Detalhe da pesquisa
1.
Emergency Medical Services Responder Manual Ventilation Performance.
Prehosp Emerg Care
; 27(4): 496-500, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-35442149
2.
Secondary Surgical Cytoreduction for Recurrent Ovarian Cancer.
N Engl J Med
; 381(20): 1929-1939, 2019 11 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-31722153
3.
Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer.
N Engl J Med
; 381(25): 2403-2415, 2019 12 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-31562800
4.
Prognostic significance of ethnicity and age in advanced stage epithelial ovarian cancer: An NRG oncology/gynecologic oncology group study.
Gynecol Oncol
; 164(2): 398-405, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-34857397
5.
Correlation of imaging and plasma based biomarkers to predict response to bevacizumab in epithelial ovarian cancer (EOC).
Gynecol Oncol
; 161(2): 382-388, 2021 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-33712274
6.
Pulse oximeter plethysmograph waveform and automated oscillometric sphygmomanometer for ankle-brachial index measurement.
Am J Emerg Med
; 40: 162-165, 2021 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-33143956
7.
Weekly vs. Every-3-Week Paclitaxel and Carboplatin for Ovarian Cancer.
N Engl J Med
; 374(8): 738-48, 2016 Feb 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-26933849
8.
Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240).
Lancet
; 390(10103): 1654-1663, 2017 Oct 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-28756902
9.
Treatment of Scorpion Envenomations in the Middle East: Understanding the Stinging Controversy.
Wilderness Environ Med
; 34(2): 258-260, 2023 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-36872164
10.
Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial.
Lancet Oncol
; 18(6): 779-791, 2017 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-28438473
11.
Weekly vs. Every-3-Week Paclitaxel for Ovarian Cancer.
N Engl J Med
; 374(26): 2603-4, 2016 06 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-27355549
12.
Incorporation of bevacizumab in the primary treatment of ovarian cancer.
N Engl J Med
; 365(26): 2473-83, 2011 Dec 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-22204724
13.
Ovarian cancer clinical trial endpoints: Society of Gynecologic Oncology white paper.
Gynecol Oncol
; 132(1): 8-17, 2014 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-24239753
14.
Assessment of Ventilation Using Adult and Pediatric Manual Resuscitators in a Simulated Adult Patient.
Respir Care
; 2024 Apr 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-38688544
15.
Independent radiologic review of the Gynecologic Oncology Group Study 0218, a phase III trial of bevacizumab in the primary treatment of advanced epithelial ovarian, primary peritoneal, or fallopian tube cancer.
Gynecol Oncol
; 131(1): 21-6, 2013 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-23906656
16.
Cytokine use and survival in the first-line treatment of ovarian cancer: a Gynecologic Oncology Group Study.
Gynecol Oncol
; 127(3): 495-501, 2012 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-23000389
17.
CA125 regression in ovarian cancer patients treated with intravenous versus intraperitoneal platinum-based chemotherapy: a gynecologic oncology group study.
Gynecol Oncol
; 124(2): 216-20, 2012 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-22033034
18.
Olaparib With or Without Cediranib Versus Platinum-Based Chemotherapy in Recurrent Platinum-Sensitive Ovarian Cancer (NRG-GY004): A Randomized, Open-Label, Phase III Trial.
J Clin Oncol
; 40(19): 2138-2147, 2022 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35290101
19.
Phase III Randomized Trial of Maintenance Taxanes Versus Surveillance in Women With Advanced Ovarian/Tubal/Peritoneal Cancer: A Gynecologic Oncology Group 0212:NRG Oncology Study.
J Clin Oncol
; 40(35): 4119-4128, 2022 12 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-35759733
20.
Nuclear P27 expression in benign, borderline (LMP) and invasive tumors of the ovary and its association with prognosis: a gynecologic oncology group study.
Gynecol Oncol
; 121(2): 395-401, 2011 May 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-21310472